GR3029666T3 - Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine - Google Patents

Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine

Info

Publication number
GR3029666T3
GR3029666T3 GR990400750T GR990400750T GR3029666T3 GR 3029666 T3 GR3029666 T3 GR 3029666T3 GR 990400750 T GR990400750 T GR 990400750T GR 990400750 T GR990400750 T GR 990400750T GR 3029666 T3 GR3029666 T3 GR 3029666T3
Authority
GR
Greece
Prior art keywords
prevention
treatment
combination
receptor antagonist
migraine
Prior art date
Application number
GR990400750T
Other languages
English (en)
Inventor
Marlene Lois Cohen
Kirk Willis Johnson
Lee Alan Phebus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GR3029666T3 publication Critical patent/GR3029666T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GR990400750T 1994-10-05 1999-03-12 Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine GR3029666T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/318,391 US5744482A (en) 1994-10-05 1994-10-05 Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine

Publications (1)

Publication Number Publication Date
GR3029666T3 true GR3029666T3 (en) 1999-06-30

Family

ID=23237987

Family Applications (1)

Application Number Title Priority Date Filing Date
GR990400750T GR3029666T3 (en) 1994-10-05 1999-03-12 Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine

Country Status (12)

Country Link
US (1) US5744482A (el)
EP (1) EP0710479B1 (el)
AT (1) ATE175347T1 (el)
AU (1) AU4130196A (el)
DE (1) DE69507112T2 (el)
DK (1) DK0710479T3 (el)
ES (1) ES2125567T3 (el)
GR (1) GR3029666T3 (el)
IL (1) IL115451A0 (el)
SI (1) SI0710479T1 (el)
WO (1) WO1996011000A1 (el)
ZA (1) ZA958173B (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US6492332B1 (en) 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
WO1996019233A2 (en) * 1994-12-12 1996-06-27 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain, inflammation and spasm
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
WO1996041633A1 (en) * 1995-06-08 1996-12-27 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6413961B1 (en) * 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
DE19917347A1 (de) * 1999-04-16 2000-11-09 Gsf Forschungszentrum Umwelt Verfahren und Vorrichtung zum trockenen Anbringen von Substanzen an inhalierbare pulverförmige Trägerstoffe
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
AU2002351412B2 (en) 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20070065463A1 (en) * 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
JP2010538985A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 抗ｈｉｖ剤としての副甲状腺ホルモン（１−３４）の使用

Also Published As

Publication number Publication date
DE69507112T2 (de) 1999-06-10
DE69507112D1 (de) 1999-02-18
DK0710479T3 (da) 1999-08-30
AU4130196A (en) 1996-05-02
EP0710479A1 (en) 1996-05-08
US5744482A (en) 1998-04-28
SI0710479T1 (en) 1999-06-30
WO1996011000A1 (en) 1996-04-18
EP0710479B1 (en) 1999-01-07
ES2125567T3 (es) 1999-03-01
ATE175347T1 (de) 1999-01-15
IL115451A0 (en) 1995-09-28
ZA958173B (en) 1997-04-01

Similar Documents

Publication Publication Date Title
SI0710479T1 (en) Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine
AU2002318211B2 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
AP2001002129A0 (en) 5HT1 receptor agonists and metoclopramide for the treatment of migrane.
IL142921A0 (en) USES FOR Eph RECEPTOR ANTAGONISTS AND AGONISTS TO TREAT VASCULAR DISORDERS
AP2002002642A0 (en) A phamaceutical composition for treatment of acute, chronic pain and/ or neuropathic pain and migraines
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
BR0200283A (pt) Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
BR0106462A (pt) Composições farmacêuticas para distúrbios do snc e outros distúrbios
BRPI0409125A (pt) terapia de combinação para constipação compreendendo um laxativo e um antagonista de opióide periférico
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
BR0311898A (pt) Tratamento de associação para depressão e ansiedade com antagonistas de nk1 e nk3
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO2001045684A3 (en) Formulations of adenosine a1 agonists
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
GB9930077D0 (en) Medicaments
EE03205B1 (et) Ropivakaiini kasutamine valuvaigistina kasutatava ravimpreparaadi valmistamiseks
EP1051995A3 (en) 5HT1 receptor agonists and a cox-2 inhibitor or NSAID for the treatment of migraine
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
WO2001045682A3 (en) Formulations of adenosine a1 agonists